It has already been heralded as the 'turning point' in the decades-long war against .But questions about whether donanemab — and two similar drugs — are really the answer to combating the devastating disease remain unanswered.Landmark trial findings published today revealed that donanemab, given as a once-monthly infusion, slowed the decline of by up to 60 per cent.
Load More
Load More